World’s First Integrated Imaging Service for Long-COVID approved by UK’s MHRA.
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of COVERSCAN MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum.
With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long-COVID”, COVERSCAN MD quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.
Perspectum’s COVERSCAN MD technology enables healthcare providers to identify coronavirus-related systemic organ damage through scans of patients’ hearts, lungs, livers, as well as other internal organs, and to assess the impact of SARS-CoV-2 infections.
With the use of COVERSCAN MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long-COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.
Related postsSee all latest
Here are some related posts
Optellum receives FDA clearance for Virtual Nodule Clinic
March 24, 2021
NCIMI partner Optellum receives FDA clearance for the world’s first AI-powered clinical decision support software for early lung cancer diagnosis…
Endometriosis Awareness Month
March 18, 2021
What is the ‘value’ of health data webinar
March 10, 2021
International Women’s Day 2021
March 8, 2021